Hims & Hers Q2 GLP-1 Revenue Falls Short of Expectations.
ByAinvest
Wednesday, Aug 6, 2025 1:03 pm ET1min read
HIMS--
Despite the revenue miss, the company reported strong growth in core areas. Revenue jumped 73% year-over-year to $544.8 million, but it fell short of Wall Street's expectations of $552 million. The company also delivered adjusted earnings per share (EPS) of 17 cents, beating the 15 cents estimate, and adjusted EBITDA of $82 million, more than doubling from the previous year's $39.3 million [2].
The stock market's negative reaction to the GLP-1 revenue miss suggests growing concerns about the company's strategy and execution in this area. Hims & Hers has faced scrutiny for distributing cheaper, unapproved versions of popular diabetes and weight-loss drugs, including GLP-1 therapies. While the FDA had previously resolved supply issues, some telehealth players, including Hims, continue to offer personalized doses [2].
The company's guidance for the third quarter also fell short of expectations, with EBITDA guidance ($60M-$70M) falling short of StreetAccount's $77.1 million forecast. Hims & Hers will need to convince investors that its fast growth won't be overshadowed by regulatory headwinds [2].
Analysts remain divided on the future of HIMS stock. The average target price for Hims & Hers Health Inc. is $48.49, with a high estimate of $85.00 and a low estimate of $28.00. GuruFocus estimates the company's fair value at $36.01 [2].
Hims & Hers Health faces ongoing challenges in its GLP-1 strategy and execution. The company must address these concerns and provide clear evidence of its long-term growth prospects to regain investor confidence.
References:
[1] https://stockanalysis.com/stocks/hims/
[2] https://www.tradingview.com/news/gurufocus:259e0cac6094b:0-hims-hers-stock-nosedives-after-q2-revenue-miss-despite-73-growth/
Hims & Hers Health reported Q2 results showing a larger-than-expected hiccup in GLP-1 revenue, causing a -13% drop in the telehealth platform's stock. The company's GLP-1 strategy is on dubious grounds, as the revenue miss was unexpected and the stock market reacted negatively. This may indicate challenges in the company's strategy or execution.
Hims & Hers Health, Inc. (HIMS) reported its second-quarter 2025 earnings on August 4, 2025, revealing a larger-than-expected dip in GLP-1 revenue. This news led to a significant drop in the company's stock, with shares falling by approximately 13% in after-hours trading [1].Despite the revenue miss, the company reported strong growth in core areas. Revenue jumped 73% year-over-year to $544.8 million, but it fell short of Wall Street's expectations of $552 million. The company also delivered adjusted earnings per share (EPS) of 17 cents, beating the 15 cents estimate, and adjusted EBITDA of $82 million, more than doubling from the previous year's $39.3 million [2].
The stock market's negative reaction to the GLP-1 revenue miss suggests growing concerns about the company's strategy and execution in this area. Hims & Hers has faced scrutiny for distributing cheaper, unapproved versions of popular diabetes and weight-loss drugs, including GLP-1 therapies. While the FDA had previously resolved supply issues, some telehealth players, including Hims, continue to offer personalized doses [2].
The company's guidance for the third quarter also fell short of expectations, with EBITDA guidance ($60M-$70M) falling short of StreetAccount's $77.1 million forecast. Hims & Hers will need to convince investors that its fast growth won't be overshadowed by regulatory headwinds [2].
Analysts remain divided on the future of HIMS stock. The average target price for Hims & Hers Health Inc. is $48.49, with a high estimate of $85.00 and a low estimate of $28.00. GuruFocus estimates the company's fair value at $36.01 [2].
Hims & Hers Health faces ongoing challenges in its GLP-1 strategy and execution. The company must address these concerns and provide clear evidence of its long-term growth prospects to regain investor confidence.
References:
[1] https://stockanalysis.com/stocks/hims/
[2] https://www.tradingview.com/news/gurufocus:259e0cac6094b:0-hims-hers-stock-nosedives-after-q2-revenue-miss-despite-73-growth/
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet